The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi
Open Access
- 19 September 2019
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Neglected Tropical Diseases
- Vol. 13 (9), e0007226
- https://doi.org/10.1371/journal.pntd.0007226
Abstract
Chagas disease, caused by Trypanosoma cruzi, is a neglected tropical disease that affects 5–6 million people in endemic areas of the Americas. Presently, chemotherapy relies on two compounds that were proposed as trypanocidal drugs four decades ago: nifurtimox and benznidazole. Both drugs are able to eliminate parasitemia and to avoid seroconversion in infected people when used in the acute phase; however, their use in the chronic phase (the time when the majority of cases are diagnosed) is limited due to their serious side effects. Memantine is a glutamate receptor antagonist in the central nervous system of mammals that has been used for the treatment of Alzheimer’s disease. Our group previously reported memantine as a trypanocidal drug that is able to induce apoptosis-like death in T. cruzi. In the present work, we further investigated the effects of memantine on the infection of RAW 264.7 macrophages and in vivo (in BALB/c mice). Here, we showed that memantine is able to diminish NO and Ca2+ entry in both LPS-activated and non-activated cells. These results, together with the fact that memantine was also able to reduce the infection of macrophages, led us to propose that this drug is able to activate a pro-oxidant non-NO-dependent cell defense mechanism. Finally, infected mice that were treated with memantine had diminished parasitemia, cardiac parasitic load, and inflammatory infiltrates. In addition, the treated mice had an increased survival rate. Taken together, these results indicate memantine to be a candidate drug for the treatment of Chagas disease. Chagas disease affects approximately 5 million people and is caused by the protist parasite Trypanosoma cruzi. Until now, there are no vaccines to prevent the human infection, and the therapy relies on the use of two drugs discovered more than 50 years ago, nifurtimox and benznidazole. Both drugs are efficient during the acute phase of the disease, however their efficacy in the chronic phase, when most of patients are diagnosed is controversial. In addition, both drugs are toxic, causing severe side effects during the treatment. For these reasons, new drugs against T. cruzi are urgently needed. In this work, we report a series of experiments supporting the repositioning of memantine, a drug used for treating Alzheimer´s disease, to treat the T. cruzi infection in an experimental infection model. Our data show that infected mice treated with memantine have diminished their parasitemia, cardiac parasitic load and inflammatory infiltrates and more importantly, they have diminished their mortality. Taken together, these results prompt memantine as a promising drug for treating Chagas disease.Keywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2016/06034-2)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (308351/2013-4)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (404769/2018-7)
- United Kingdom Research and Innovation (Global Challenges Research Fund under grant agreement ‘A Global Network for Neglected Tropical Diseases: MR/P027989/1)
This publication has 39 references indexed in Scilit:
- Low-Dose Memantine Attenuated Morphine Addictive Behavior Through its Anti-Inflammation and Neurotrophic Effects in RatsJournal of Neuroimmune Pharmacology, 2011
- Inhibitory effect of memantine, an NMDA-receptor antagonist, on electoporation-induced inward currents in pituitary GH3 cellsBiochemical and Biophysical Research Communications, 2011
- Ketamine inhibits tumor necrosis factor secretion by RAW264.7 murine macrophages stimulated with antibiotic-exposed strains of community-associated, methicillin-resistant Staphylococcus aureusBMC Immunology, 2011
- Chagas’ disease: an update on immune mechanisms and therapeutic strategiesJournal of Cellular and Molecular Medicine, 2010
- Chagas diseaseThe Lancet, 2010
- Drug Discovery Using Chemical Systems Biology: Repositioning the Safe Medicine Comtan to Treat Multi-Drug and Extensively Drug Resistant TuberculosisPLoS Computational Biology, 2009
- Memantine Inhibits ATP-Dependent K+Conductances in Dopamine Neurons of the Rat Substantia NigraPars CompactaThe Journal of pharmacology and experimental therapeutics, 2007
- Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicityEuropean Journal of Neuroscience, 2006
- Characterization of ionotropic glutamate receptors in human lymphocytesBritish Journal of Pharmacology, 2001
- Control of Trypanosoma cruzi Epimastigote Motility through the Nitric Oxide PathwayThe Journal of Eukaryotic Microbiology, 1997